Interaction of colistin and colistin methanesulfonate with liposomes: Colloidal aspects and implications for formulation

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3347-3359

  Wallace, Stephanie J ^a   Li, Jian ^a   Nation, Roger L ^a   Prankerd, Richard J ^a   Boyd, Ben J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Colistin; Colloid; Controlled release delivery; Liposome; Micelle; Polymyxin E; Self assembly; Stability

Indexed keywords

COLISTIMETHATE; COLISTIN; LIPOSOME;

AQUEOUS SOLUTION; ARTICLE; COLLOID; CONTROLLED DRUG RELEASE; DILUTION; DRUG DECOMPOSITION; DRUG RETENTION; DRUG STABILITY; ENCAPSULATION; ISOTHERMAL TITRATION CALORIMETRY; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84864039471     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23203     Document Type: Article

References (49)

1. Falagas ME, Kasiakou SK. 2007. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection 35(1):3-10.
2. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28(5):1008-1011.
3. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. 2005. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41(5):754-757.
4. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME. 2008. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: A prospective study. Respir Med 102(3):407-412.
5. Michalopoulos A, Kasiakou S, Mastora Z, Rellos K, Kapaskelis A, Falagas M. 2005. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 9:R53-R59.
6. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50(6):1953-1958.
7. Barnett M, Bushby SR, Wilkinson S. 1964. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 23:552-574.
8. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: The re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 6(9):589-601.
9. Nation RL, Li J. 2009. Colistin in the 21st century. Curr Opin Infect Dis 22(6):535-543.
10. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. 2008. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 52(9):3047-3051.
11. Wallace SJ, Li J, Nation RL, Prankerd RJ, Velkov T, Boyd BJ. 2010. Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: Implications for solution stability and solubilization. J Phys Chem B 114(14):4836-4840.
12. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. 1985. Nebulized colomycin for early pseudomonas colonization in cystic fibrosis. Lancet 1:865.
13. Hansen CR, Pressler T, Hoiby N. 2008. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 7(6):523-530.
14. Gaynes R, Edwards JR. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41(6):848-854.
15. Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F. 2000. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38(11):4086-4095.
16. Denton M, Kerr K, Mooney L, Keer V, Rajgopal A, Brownlee K, Arundel P, Conway S. 2002. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 34(4):257-261.
17. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 60(5):1163-1167.
18. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou H. 2007. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: First report of a multiclonal cluster. J Antimicrob Chemother 59(4):786-790.
19. Hsueh PR, Tseng SP, Teng LJ, Ho SW. 2005. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan. Clin Microbiol Infect 11(8):670-673.
20. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 66(9):2070-2074.
21. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, Samonis G, Falagas ME. 2008. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: A matched case-control study. Crit Care Med 36(3):807-811.
22. Manno G, Morelli P, Mentasti M, Casciaro GM, Rossolini N, Cirilli R, Gagliaridini R, D'Aprile A, Gioffre F, Scuteri D, Melioli G. 2008. Emergence of colistin-resistant Pseudomonas aeruginosa from Italian cystic fibrosis patients. J Cyst Fibros 7:S13-S14.
23. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. 2008. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 7(5):391-397.
24. Hawley JS, Murray CK, Jorgensen JH. 2008. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52(1):351-352.
25. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. 2008. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: Studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61(3):636-642.
26. Tan CH, Li J, Nation RL. 2007. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 51(9):3413-3415.
27. Petrosillo N, Ioannidou E, Falagas ME. 2008. Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14(9):816-827.
28. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. 2009. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54(3):1117-1124.
29. Schiffelers RM, Storm G, ten Kate MT, Stearne-Cullen LE, den Hollander JG, Verbrugh HA, Bakker-Woudenberg IA. 2002. Liposome-enabled synergistic interaction of antimicrobial agents. J Liposome Res 12(1-2):121-127.
30. Sachetelli S, Khalil H, Chen T, Beaulac C, Senechal S, Lagace J. 2000. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta 1463(2):254-266.
31. Jones MN. 2005. Use of liposomes to deliver bactericides to bacterial biofilms. Methods Enzymol 391:211-228.
32. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. 2008. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 61(4):859-868.
33. Bangham AD. 1968. Membrane models with phospholipids. Prog Biophys Mol Biol 18:29-95.
34. Cui J, Li C, Deng Y, Wang Y, Wang W. 2006. Freeze-drying of liposomes using tertiary butyl alcohol/water cosolvent systems. Int J Pharm 312(1-2):131-136.
35. Delgado AV, Gonzalez-Caballero E, Hunter RJ, Koopal LK, Lyklema J. 2005. Measurement and interpretation of electrokinetic phenomena (IUPAC technical report). Pure Appl Chem 77(10):1753-1805.
36. Boyd BJ. 2003. Characterisation of drug release from cubosomes using the pressure ultrafiltration method. Int J Pharm 260(2):239-247.
37. Wallace SJ, Li J, Nation RL, Boyd BJ. Drug release from nanomedicines: Selection of appropriate encapsulation and release methodology. Drug Deliv Transl Res (in press, DOI: 10.1007/s13346-012-0064-4).
38. McAllister SM, Alpar HO, Brown MRW. 1994. Liposomal polymyxin B: Characterisation and pulmonary delivery. Proceedings of the International Symposium of the Controlled Release of Bioactive Materials: Controlled Release Society, pp 336-337.
39. Omri A, Suntres ZE, Shek PN. 2002. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 64(9):1407-1413.
40. Wang D, Kong L, Wang J, He X, Li X, Xiao Y. 2009. Polymyxin E sulfate-loaded liposome for intravenous use: Preparation, lyophilization, and toxicity assessment in vivo. PDA J Pharm Sci Technol 63(2):159-167.
41. Hancock REW. 1997. Peptide antibiotics. Lancet 349(9049):418-422.
42. Mestres C, Alsina MA, Busquets MA, Muranyi I, Reig F. 1998. Interaction of colistin with lipids in liposomes and monolayers. Int J Pharm 160(1):99-107.
43. Colome C, Alsina MA, Busquets MA, Haro I, Reig F. 1993. Interaction of aminoglycosides and colistin with model membranes: Liposomes and monolayers. Int J Pharm 90:59-71.
44. Pache W, Chapman D, Hillaby R. 1972. Interaction of antibiotics with membranes: Polymyxin B and gramicidin S. Biochim Biophys Acta 255(1):358-364.
45. Lin MS, Chiu HM, Fan FJ, Tsai HT, Wang SS, Chang Y, Chen WY. 2007. Kinetics and enthalpy measurements of interaction between P-amyloid and liposomes by surface plasmon resonance and isothermal titration microcalorimetry. Colloids Surf B Biointerfaces 58(2):231-236.
46. Olofsson G, Wang G. 1994. Interactions between surfactants and uncharged polymers in aqueous-solution studied by microcalorimetry. Pure Appl Chem 66(3):527-532.
47. Storm DR, Rosenthal KS, Swanson PE. 1977. Polymyxin and related peptide antibiotics. Annu Rev Biochem 46:723-763.
48. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, Li J, Nation RL. 2011. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55(11):5134-5142.
49. Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, Paterson DL, Nation RL, Li J. 2011. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 55(12):5685-5695.